[ad_1]
www.adamaspharma.com.” data-reactid=”13″>About Adamas Pharmaceuticals, Inc.
At Adamas, our purpose and vision are clear: deliver innovative medicines that make a clinically meaningful difference for patients, caregivers and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. In 2018, Adamas successfully launched GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI is also the only medicine clinically proven to reduce both dyskinesia and OFF. For more information, please visit www.adamaspharma.com.
peter.vozzo@westwicke.com” data-reactid=”15″>Investors:
Peter Vozzo
Westwicke Partners
443-213-0505
peter.vozzo@westwicke.com
smathieson@adamaspharma.com” data-reactid=”16″>Media:
Sarah Mathieson
Vice President, Communications & Engagement
510-450-3528
smathieson@adamaspharma.com
[ad_2]
Read More: Adamas Announces New Employment Inducement Grant
